Rankings / Longevity — Supplements
ER-100 (partial epigenetic reprogramming)
Longevity · Partial epigenetic reprogramming
Tier D
High-risk evidence profile
Bottom line
Read Off Label grades ER-100 (partial epigenetic reprogramming) as D (2.9/10) based on preclinical evidence, high benefit magnitude, and a high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 2/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Life Biosciences (co-founded by David Sinclair).
Studied, labeled, or reported-use context: Intravitreal AAV-OSK plus 8-week oral doxycycline activation (NAION/glaucoma trial) — Investigational; not individualized guidance.
Frontier potential — editorial judgment, not evidence
This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.
What the ceiling rests on
Partial reprogramming is the only intervention class that has restored youthful gene-expression and methylation patterns in aged mammalian tissue, and in some models restored function (optic-nerve regeneration, improved survival in progeroid mice). If age is partly an epigenetic state, this is the class that acts on the cause rather than a downstream symptom.
Why it may not get there
The whole class carries a teratoma and dedifferentiation risk that is well documented in animals and unsolved in humans; delivery, dose, and duration control are all open problems. First-in-human dosing began in 2026 and no efficacy or safety data have been published — the ceiling here rests entirely on animal work.
What would change this Published Phase 1 safety data, including any dedifferentiation or tumour signal.
If you were testing this on yourself
Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.
Can you undo it?
Potentially permanent
Epigenetic reprogramming changes cell state. The failure modes documented in animals — dedifferentiation and teratoma formation — are by nature not undone by stopping treatment.
Can you tell if it worked?
Nothing you can measure
No endpoint exists that you could observe for the reason this is taken. An experiment without a readout cannot tell you anything, however it turns out.
What would fool you This is a clinical-trial asset, not a purchasable compound, and no self-experiment is possible or should be attempted. It appears on this site because the science matters, not because it is available.
What the evidence says
Life Biosciences (co-founded by David Sinclair). First partial-reprogramming therapy dosed in a human: FDA cleared the IND Jan 2026 and the first Phase 1 patient was dosed Jun 9 2026 — believed to be the world's first in-human test of partial epigenetic reprogramming. Phase 1 (NCT07290244) in non-arteritic anterior ischemic optic neuropathy (NAION) and open-angle glaucoma; safety/tolerability primary, with visual-function endpoints; $80M Series D Apr 2026. No published human efficacy yet. Distinct from the preclinical Yamanaka-factor class row. Frontier — the field's most ambitious longevity modality. Company-sponsored.
Mechanism
AAV-delivered OSK (Oct4/Sox2/Klf4) Yamanaka factors, transiently activated by oral doxycycline, reset age-associated epigenetic marks in retinal cells without dedifferentiation, aiming to restore youthful function rather than slow damage.
Studied, labeled, or reported dose & route
Intravitreal AAV-OSK plus 8-week oral doxycycline activation (NAION/glaucoma trial)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about ER-100 (partial epigenetic reprogramming)'s effects?
- Read Off Label rates the evidence for ER-100 (partial epigenetic reprogramming) as Preclinical and the benefit magnitude as high, producing an overall grade of D (2.9/10). Life Biosciences (co-founded by David Sinclair).
- What safety findings are reported for ER-100 (partial epigenetic reprogramming)?
- ER-100 (partial epigenetic reprogramming) has a high risk profile in the database. High (first-in-human reprogramming; oncogenic/dedifferentiation risk theoretical) Legal status: Investigational (Phase 1; first patient dosed Jun 9 2026).
- What does the low Safety score for ER-100 (partial epigenetic reprogramming) represent?
- The Safety score is 2/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for ER-100 (partial epigenetic reprogramming)?
- Intravitreal AAV-OSK plus 8-week oral doxycycline activation (NAION/glaucoma trial) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does ER-100 (partial epigenetic reprogramming) work?
- AAV-delivered OSK (Oct4/Sox2/Klf4) Yamanaka factors, transiently activated by oral doxycycline, reset age-associated epigenetic marks in retinal cells without dedifferentiation, aiming to restore youthful function rather than slow damage.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.